SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Crist WM, Anderson JR, Meza JL, et al. Intergroup Rhabdomyosarcoma Study-IV: results for patients with nonmetastatic disease. J Clin Oncol. 2001; 19: 3091-3102.
  • 2
    Hayes-Jordan A, Andrassy R. Rhabdomyosarcoma in children. Curr Opin Pediatr. 2009; 21: 373-378.
  • 3
    Meza JL, Anderson J, Pappo AS, Meyer WH. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on Intergroup Rhabdomyosarcoma Studies III and IV: the Children's Oncology Group. J Clin Oncol. 2006; 24: 3844-3851.
  • 4
    Stevens MC, Rey A, Bouvet N, et al. Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology-SIOP. Malignant Mesenchymal Tumor 89. J Clin Oncol. 2005; 23: 2618-2628.
  • 5
    Raney RB, Anderson JR, Barr FG, et al. Rhabdomyosarcoma and undifferentiated sarcoma in the first 2 decades of life: a selective review of Intergroup Rhabdomyosarcoma Study Group experience and rationale for Intergroup Rhabdomyosarcoma Study V. J Pediatr Hematol Oncol. 2001; 23: 215-220.
  • 6
    Joshi D, Anderson JR, Paidas C, Breneman J, Parham DM, Crist W. Age is an independent prognostic factor in rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Pediatr Blood Cancer. 2004; 42: 64-73.
  • 7
    Ferrari A, Miceli R, Meazza C, et al. Soft tissue sarcomas of childhood and adolescence: the prognostic role of tumor size in relation to patient body size. J Clin Oncol. 2009; 27: 371-376.
  • 8
    Ferrari A, Miceli R, Meazza C, et al. Comparison of the prognostic value of assessing tumor diameter versus tumor volume at diagnosis or in response to initial chemotherapy in rhabdomyosarcoma. J Clin Oncol. 2010; 28: 1322-1328.
  • 9
    Arndt CA, Stoner JA, Hawkins DS, et al. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: Children's Oncology Group Study D9803. J Clin Oncol. 2009; 27: 5182-5188.
  • 10
    Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group Data Base. J Clin Oncol. 1990; 8: 1563-1574.
  • 11
    Segal MR. Regression trees for censored data. Biometrics. 1988; 44: 35-47.
  • 12
    Kwak LW, Jalpern J, Olshen RA, Horning SJ. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol. 1990; 8: 963-977.
  • 13
    Lawrence W Jr, Gehan EA, Hays DM, Beltangady M, Maurer HM. Prognostic significance of staging factors of the UICC staging system in childhood rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS-II). J Clin Oncol. 1987; 1: 46-54.
  • 14
    Reboul-Marty J, Quintana E, Mosseri V, et al. Prognostic factors of alveolar rhabdomyosarcoma in childhood. An International Society of Pediatric Oncology study. Cancer. 1991; 68: 493-498.
  • 15
    Dantonello TM, Int-Veen C, Winkler P, et al. Initial patient characteristics can predict pattern and risk of relapse in localized rhabdomyosarcoma. J Clin Oncol. 2008; 26: 406-413. 2008; 261911-413. Erratum in: J Clin Oncol. 2008;261911.
  • 16
    Ferrari A, Miceli R, Casanova M, et al. Adult-type soft tissue sarcomas in paediatric age: a nomogram-based prognostic comparison with adult sarcoma. Eur J Cancer. 2007; 43: 2691-2697.